| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide manufacturers
- AZD4721
-
-
2026-04-22
- CAS:1418112-77-2
- Purity:
- Supply Ability: 10g
|
| | N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide Basic information |
| | N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white |
| | N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide Usage And Synthesis |
| Uses | Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease[1]. | | in vivo | Assessment of Pharmacokinetics (PK) profile of Vimnerixin in rat and dog[1] .
| In Vivo PK | Rat | Dog | | Predicted hepatic metabolic CL (ml/min per kilogram) | 1.7 | 0.80 | | Observed CL (ml/min per kilogram) | 2.4 | 0.50 | | CLrenal (mL/min per kilogram) | <0.01 | <0.01 | | CLbiliary (mL/min per kilogram) | <0.01 | 0.04 | | In vivo/in vitro unbound CLintc | 1.4 | 0.6 | | VSS (l/kg) | 0.19 | 0.15 | | T1/2 (h) (PO) | 1.3 | 3.7 | | (2.7) | (8.4) | | F (%) | 45 | 82 |
| | References | [1] Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873. DOI:10.1124/dmd.119.087163 |
| | N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide Preparation Products And Raw materials |
|